LongBio Pharma (Suzhou) Co., Ltd. (HKG:1779)

Hong Kong flag Hong Kong · Delayed Price · Currency is HKD
142.80
+2.80 (2.00%)
Jun 18, 2026, 4:08 PM HKT
Market Cap10.39B
Revenue (ttm)n/a
Net Income-195.39M
EPS-3.45
Shares Out 74.19M
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume276,510
Open140.00
Previous Close140.00
Day's Range137.00 - 142.90
52-Week Range96.06 - 158.00
Betan/a
Analystsn/a
Price Targetn/a
Earnings Daten/a

About LongBio Pharma (Suzhou)

LongBio Pharma (Suzhou) Co., Ltd. engages in discovery and development of biopharmaceuticals that targets allergic and autoimmune diseases in the People's Republic of China and Hong Kong. The company's products includes LP-003, an anti-IgE antibody with novel sequencing; LP-005, bi-functional antibody fusion protein; LP-00A, a bi-functional antibody for allergic diseases; LP-00C, a bi-functional antibody or fusion protein for B-cell mediated autoimmune diseases; and LP-00D, a bi-functional antibody or fusion protein complement inhibitor for spe... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2020
Employees 85
Stock Exchange Hong Kong Stock Exchange
Ticker Symbol 1779
Full Company Profile

Financial Performance

Financial numbers in CNY Financial Statements